Aerie Pharmaceuticals Other Liabilities

Aerie Pharmaceuticals (AERI) currently reports a other liabilities of $74M as of September 2022. That compares with $56M in the prior-year period — up 32.7% year over year. Use the charts on this page to explore Aerie Pharmaceuticals's other liabilities history and peer comparisons.

Aerie Pharmaceuticals's other liabilities increased from $56M to $74M — a 32.7% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aerie Pharmaceuticals reported $74M in other liabilities as of September 2022. That compares with $56M in the prior-year period — up 32.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other liabilities of $74M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Aerie Pharmaceuticals, and consider following AERI for alerts when major investors trade the stock.

Aerie Pharmaceuticals is classified in the Healthcare sector. On other liabilities, it currently shows $74M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AERI with unrelated industries.